Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04886401

Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC — PREDICTION  

Advanced Non Small Cell Lung Cancer Clinical Trial

Official title:
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With Non Small Cell Lung Cancer Mass Tissue Imaging HyperIONTM

Clinical Trial Summary

Therapeutic antibodies that block the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway have revolutionized immuno-oncology by inducing robust and durable responses in patients with various cancer including advanced non-small-cell lung cancer (NSCLC). However, these responses only occur in a subset of patients, even in case of PD-L1 overexpression. Elucidating the determinants of response and resistance but also of severe immune-mediated adverse events is key to improving outcomes and developing new treatment strategies. Biomarkers that predict immune checkpoint inhibitors efficacy and toxicity are urgently needed and could emerge from characterization of tumor microenvironment. The purpose of PREDICTION project is to elucidate response and toxicity predictive immunophenotypic signatures using a new in situ multiplexed strategy with imaging mass cytometry Hyperion. Patients treated with anti-PD-1 pembrolizumab will be selected on their response and toxicity profiles. Then, tumor samples will be analysed with Hyperion technology, allowing delineation of cell subpopulations and cell-cell interactions, highlighting tumor heterogeneity and to determine correlations between response and toxicity features. The number of co-analysable markers enables global vision on the same tissue section. A better understanding of the tumor microenvironment complex system will lead to discover new predictive biomarkers potentially transferable to current practice.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04886401
Study type Observational
Source University Hospital, Brest
Contact Margaux GEIER, MD
Phone 02 30 33 80 30
Email margaux.geier@chu-brest.fr
Status Recruiting
Phase
Start date April 16, 2021
Completion date May 16, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT03326752 - Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC Phase 1
Completed NCT02157883 - Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Phase 1
Completed NCT00072631 - Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT02163733 - Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06107374 - Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG Phase 2
Completed NCT01802632 - AZD9291 First Time In Patients Ascending Dose Study Phase 1/Phase 2
Recruiting NCT06406166 - Lifei Xiaoji Wan in Treatment of Advanced NSCLC N/A
Terminated NCT04785365 - Long-Term Follow-Up Study of Patients Receiving ATL001 Phase 2
Recruiting NCT04032847 - ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC Phase 1/Phase 2
Completed NCT01631136 - Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer Phase 3
Recruiting NCT04239443 - Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer Phase 2
Completed NCT03452150 - D-0316 First Time in Patients Ascending Dose Study Phase 1
Completed NCT04144608 - Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT04755738 - Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer Phase 2
Completed NCT03652857 - Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Completed NCT03351361 - Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients Phase 3
Completed NCT02407327 - Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Active, not recruiting NCT02143466 - AZD9291 in Combination With Ascending Doses of Novel Therapeutics Phase 1
Recruiting NCT05004974 - Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT05777603 - Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Phase 1